Safety and Efficacy of Chloroquine Associated With Dehydroepiandrosterone Sulphate to Treat Uncomplicated Falciparum Malaria
Etude de l'Activite (Efficacite et Tolerance) de l'Association de la Chloroquine Avec la Dehydroepiandrosterone-Sulfate (Dheas) Dans le Traitement de l'Acces Palustre Simple A Plasmodium Falciparum
Sponsor: Université Victor Segalen Bordeaux 2
Suspended
At the end of the year 2002, Cameroon switched from chloroquine to amodiaquine as first-line therapy for of uncomplicated malaria.
Listed as NCT00442403, this PHASE3 trial focuses on Malaria and remains suspended. Sponsored by Université Victor Segalen Bordeaux 2, it has been updated 10 times since 2002, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Suspended PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Suspended PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Suspended PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Suspended PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Suspended PHASE3
▶ Show 5 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Suspended PHASE3
-
Sep 2020 — Nov 2020 [monthly]
Suspended PHASE3
-
May 2018 — Sep 2020 [monthly]
Suspended PHASE3
-
Aug 2017 — May 2018 [monthly]
Suspended PHASE3
-
Jan 2017 — Aug 2017 [monthly]
Suspended PHASE3
First recorded
Apr 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Université Victor Segalen Bordeaux 2
For direct contact, visit the study record on ClinicalTrials.gov .